INOVIO PHARMACEUTICALS, INC. Revenue From Contract With Customer Excluding Assessed Tax

• INOVIO PHARMACEUTICALS, INC. showed a decrease of -70.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
• This data is from INOVIO PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: $10.38 million | Q2 2017: $20.41 million | Q3 2017: $2.64 million | Q4 2017: $8.79 million | Q1 2018: $1.53 million | Q2 2018: $24.45 million | Q3 2018: $2.00 million | Q4 2018: $2.50 million | Q1 2019: $2.83 million | Q2 2019: $135.7 thousand | Q3 2019: $866.9 thousand | Q4 2019: $279.5 thousand | Q1 2020: $1.33 million | Q2 2020: $267.2 thousand | Q3 2020: $236.2 thousand | Q4 2020: $5.58 million | Q1 2021: $371.1 thousand | Q2 2021: $272.8 thousand | Q3 2021: $291.7 thousand | Q1 2022: $199.1 thousand | Q2 2022: $784.4 thousand | Q3 2022: $9.15 million | Q1 2023: $114.9 thousand | Q2 2023: $226.0 thousand | Q3 2023: $388.4 thousand | Q1 2024: $0.00 | Q2 2024: $100.8 thousand | Q3 2024: $0.00 | Q1 2025: $65.3 thousand | Q2 2025: $0.00 | Q3 2025: $0.00.
• Over the full 10 years of available data (2016 to 2025), INOVIO PHARMACEUTICALS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 99.8%.
• Historical annual values: Fiscal year 2025: $65.3 thousand | Fiscal year 2024: $217.8 thousand | Fiscal year 2023: $832.0 thousand | Fiscal year 2022: $10.26 million | Fiscal year 2021: $1.77 million | Fiscal year 2020: $7.41 million | Fiscal year 2019: $4.11 million | Fiscal year 2018: $30.48 million | Fiscal year 2017: $42.22 million | Fiscal year 2016: $35.37 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026